Correlation of serum ribavirin concentration with pretreatment renal function estimates in patients with chronic hepatitis C receiving combination antiviral therapy with peginterferon and ribavirin

Journal of Viral Hepatitis

Volumn 15, Issue 9, 2008, Pages 651-658

  Toyoda, H ^a   Kumada, T ^a   Kiriyama, S ^a   Sone, Y ^a   Tanikawa, M ^a   Hisanaga, Y ^a   Kanamori, A ^a   Atsumi, H ^a   Nakano, S ^a   Arakawa, T ^a   Honda, T ^b   Hayashi, K ^b   Katano, Y ^b   Goto, H ^b  

^a OGAKI MUNICIPAL HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic hepatitis C; Creatinine; Cystatin C; Renal function; Ribavirin

Indexed keywords

CYSTATIN C; PEGINTERFERON; RIBAVIRIN;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; FEMALE; HEPATITIS C; HUMAN; KIDNEY FUNCTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CREATININE; CYSTATINS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; KIDNEY FUNCTION TESTS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RIBAVIRIN; SERUM; STATISTICS AS TOPIC;

EID: 49649100865     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.01004.x     Document Type: Article

References (37)

1. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998 339 : 1485 1492.
2. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998 352 : 1426 1432.
3. Reichard O, Norkrans G, Fryden A et al. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998 351 : 83 87.
4. Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998 339 : 1493 1499.
5. Schvarcz R, Ando Y, Sonnerborg A, Weiland O. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol 1995 23 (Suppl. 2 17 21.
6. Barbaro G, Di Lorenzo G, Belloni G et al. Interferon alfa-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial. Am J Med 1999 107 : 112 118.
7. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 965.
8. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
9. Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990 12 : 1139 1146.
10. Lindahl K, Schvarcz R, Bruchfeld A, Stahle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat 2004 11 : 84 87.
11. Arase Y, Ikeda K, Tsubota A et al. Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology 2005 48 : 138 144.
12. Bruchfeld A, Lindahl K, Schvarcz R, Stahle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002 24 : 701 708.
13. Kamar N, Chatelut E, Manolis E, Lafont T, Izopet J, Rostaing L. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis 2004 43 : 140 146.
14. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994 20 : 15 20.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 : 31 41.
16. Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 2003 18 : 2024 2031.
17. Larsson A, Malm J, Grubb A, Hansson LO. Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L. Scand J Clin Lab Invest 2004 64 : 25 30.
18. Tsubota A, Hirose Y, Izumi N, Kumada H. Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Br J Clin Pharmacol 2003 55 : 360 367.
19. Uchida M, Hamada A, Yamasaki M, Fujiyama S, Sasaki Y, Saito H. Assessment of adverse reactions and pharmacokinetics of ribavirin in combination with interferon alpha-2b in patients with chronic hepatitis C. Drug Metab Pharmacokinet 2004 19 : 438 443.
20. Svensson J-O, Bruchfeld A, Schvarcz R, Stahle L. Determination of ribavirin in serum using highly selective solid-phase extraction and high-performance liquid chromatography. Ther Drug Monit 2000 22 : 215 218.
21. Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru C, Grubb A. Cystatin C as a marker of GFR -history, indications, and future research. Clin Biochem 2005 38 : 1 8.
22. Newman DJ, Cystatin C. Ann Clin Biochem 2002 39 : 89 104.
23. Randers E, Erlandsen EJ. Serum cystatin C as an endogenous marker of the renal function - a review. Clin Chem Lab Med 1999 37 : 389 395.
24. Coll E, Botey A, Alvarez L et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000 36 : 29 34.
25. Woitas RP, Stoffel-Wagner B, Flommersfeld S et al. Correlation of serum concentrations of cystatin C and creatinine to inulin clearance in liver cirrhosis. Clin Chem 2000 46 : 712 715.
26. Demirtas S, Bozbas A, Akbay A, Yavuz Y, Karaca L. Diagnostic value of serum cystatin C for evaluation of hepatorenal syndrome. Clin Chim Acta 2001 311 : 81 89.
27. Gerbes AL, Gulberg V, Bilzer M, Vogeser M. Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. Gut 2002 50 : 106 110.
28. Randers E, Ivarsen P, Erlandsen EJ et al. Plasma cystatin C as a marker of renal function in patients with liver cirrhosis. Scand J Clin Lab Invest 2002 62 : 129 134.
29. Orlando R, Mussap M, Plebani M et al. Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis. Clin Chem 2002 48 : 850 858.
30. MacIsaac RJ, Tsalamandris C, Thomas MC et al. Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C- and creatinine-based methods. Diabetologia 2006 49 : 1686 1689.
31. Shlipak MG, Katz R, Sarnak MJ et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006 145 : 237 246.
32. Nakamura T, Ioroi T, Sakaeda T et al. Serum cystatin C levels to predict serum concentration of digoxin in Japanese patients. Int J Med Sci 2006 3 : 92 96.
33. Hermida J, Tutor JC. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin. Ther Drug Monit 2006 28 : 326 331.
34. Takeuchi M, Fukuda Y, Nakano I, Katano Y, Hayakawa T. Elevation of serum cystatin C concentrations in patients with chronic liver disease. Eur J Gastroenterol Hepatol 2001 13 : 951 955.
35. Chu S-C, Wang C-P, Chang Y-H et al. Increased cystatin C serum concentrations in patients with hepatic diseases of various severities. Clin Chim Acta 2004 341 : 133 138.
36. Maeda Y, Kiribayashi Y, Moriya T et al. Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C. Ther Drug Monit 2004 26 : 9 15.
37. Karino Y, Toyota J, Akutsu N et al. Total clearance of ribavirin (CL/F) based ribavirin dosage improves the safety and effect of interferon and ribavirin combination therapy for chronic hepatitis C. Hepatology 2005 42 (S1 650A [Abstract].